Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPITOPE: Viaskin Peanut in peanut-allergic children aged 1–3 years
2016-003679-23Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Oct 2018
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing Viaskin Peanut 250 µg with Placebo patch (2 arms). Primary endpoint: Treatment responder rate at Month 12. Started Oct 2018; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2016-003679-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003679-23.